These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 17425490

  • 1. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.
    Staller JA, Faraone SV.
    Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490
    [Abstract] [Full Text] [Related]

  • 2. Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
    Denney CB.
    J Clin Child Psychol; 2001 Mar; 30(1):98-109. PubMed ID: 11294083
    [Abstract] [Full Text] [Related]

  • 3. Attention deficit and hyperactivity disorder: review of genetic association studies.
    Galili-Weisstub E, Segman RH.
    Isr J Psychiatry Relat Sci; 2003 Mar; 40(1):57-66. PubMed ID: 12817670
    [Abstract] [Full Text] [Related]

  • 4. A review of the biological bases of ADHD: what have we learned from imaging studies?
    Durston S.
    Ment Retard Dev Disabil Res Rev; 2003 Mar; 9(3):184-95. PubMed ID: 12953298
    [Abstract] [Full Text] [Related]

  • 5. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
    Arnsten AF.
    J Clin Psychiatry; 2006 Mar; 67 Suppl 8():7-12. PubMed ID: 16961424
    [Abstract] [Full Text] [Related]

  • 6. Drug policy and treatment bias due to the dopamine-deficit theory of child attention-deficit hyperactivity disorder.
    Rastmanesh R.
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):149-57. PubMed ID: 21432601
    [Abstract] [Full Text] [Related]

  • 7. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J.
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [Abstract] [Full Text] [Related]

  • 8. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
    Genro JP, Kieling C, Rohde LA, Hutz MH.
    Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
    [Abstract] [Full Text] [Related]

  • 9. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.
    Volkow ND, Wang GJ, Fowler JS, Ding YS.
    Biol Psychiatry; 2005 Jun 01; 57(11):1410-5. PubMed ID: 15950015
    [Abstract] [Full Text] [Related]

  • 10. Study supports medication for ADHD.
    Health News; 2000 Feb 01; 6(2):5. PubMed ID: 10734823
    [No Abstract] [Full Text] [Related]

  • 11. The stimulants revisited.
    Wilens TE, Spencer TJ.
    Child Adolesc Psychiatr Clin N Am; 2000 Jul 01; 9(3):573-603, viii. PubMed ID: 10944658
    [Abstract] [Full Text] [Related]

  • 12. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun 01; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 13. Attention deficit hyperactivity disorder in sport: a review.
    Corrigan B.
    Int J Sports Med; 2003 Oct 01; 24(7):535-40. PubMed ID: 12968213
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychiatry; 2006 Oct 01; 67 Suppl 8():32-8. PubMed ID: 16961428
    [Abstract] [Full Text] [Related]

  • 15. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychopharmacol; 2008 Jun 01; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [Abstract] [Full Text] [Related]

  • 16. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.
    Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, Buck AK, Reske SN, Fegert JM, Mottaghy FM.
    Neuroimage; 2008 Jul 01; 41(3):718-27. PubMed ID: 18424180
    [Abstract] [Full Text] [Related]

  • 17. [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder].
    Velásquez-Tirado JD, Peña JA.
    Rev Neurol; 2008 Jul 01; 41(8):493-500. PubMed ID: 16224736
    [Abstract] [Full Text] [Related]

  • 18. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder.
    van der Kooij MA, Glennon JC.
    Neurosci Biobehav Rev; 2007 Jul 01; 31(4):597-618. PubMed ID: 17316796
    [Abstract] [Full Text] [Related]

  • 19. Attention-deficit/hyperactivity disorder endophenotypes.
    Doyle AE, Willcutt EG, Seidman LJ, Biederman J, Chouinard VA, Silva J, Faraone SV.
    Biol Psychiatry; 2005 Jun 01; 57(11):1324-35. PubMed ID: 15950005
    [Abstract] [Full Text] [Related]

  • 20. [Neurobiology of attention deficit/hyperactivity disorder].
    Purper-Ouakil D, Lepagnol-Bestel AM, Grosbellet E, Gorwood P, Simonneau M.
    Med Sci (Paris); 2010 May 01; 26(5):487-96. PubMed ID: 20510147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.